A study reveals that a low-salt fasting-mimicking diet slows kidney disease progression in animal models and shows protective ...

In patients with chronic kidney disease, the loss of podocytes—part of the kidney's glomerular filtration barrier—causes irreversible disease progression. So far, physicians and researchers have found ...

Pegcetacoplan substantially reduced proteinuria in these potentially debilitating rare kidney diseases in a new phase 3 study ...

The global mitochondrial DNA market is on a promising trajectory, with an estimated valuation of USD 316.8 million in 2022. The market is expected to grow steadily at a CAGR of 7.5% from 2023 to 2033, ...

The global market for complement 3 glomerulopathy (c3g) treatment is poised for steady growth, with a projected valuation of ...

数据表明， 早在治疗14天时即可观察到Fabhalta可减少C3G患者的蛋白尿，此结果具临床意义并持续至12个月。 在研究的开放标签阶段，切换至Fabhalta的受试者也表现出蛋白尿的减少。

Our medicines reach more than 250 million people worldwide. Smith RJ, Kavanagh D, Vivarelli M, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-Month results from the ...

Novartis yesterday presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney ...

Pharmaceuticals and Sobi announced that results from the Phase 3 VALIANT study were presented as an oral presentation during ...

During the trial, patients treated with Fabhalta experienced a significant reduction in proteinuria as early as two weeks.